Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allisartan - Allist Pharmaceuticals/Shenzhen Salubris Pharmaceuticals

Drug Profile

Allisartan - Allist Pharmaceuticals/Shenzhen Salubris Pharmaceuticals

Alternative Names: Allisartan isoproxil - Allist Pharmaceuticals/Shenzhen Salubris Pharmaceuticals; Shun Li Tan®; Xinlitan

Latest Information Update: 13 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allist Pharmaceuticals
  • Developer Allist Pharmaceuticals; Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 13 Feb 2019 Chemical structure information added
  • 31 Mar 2010 Allist Pharmaceuticals completes a phase III trial in Hypertension in China (ChiCTR-TRC10000885)
  • 31 Jan 2010 Allist Pharmaceuticals completes a phase II trial in Hypertension in China (ChiCTR-TRC10000886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top